← Back to patent-cliff list
NX210c
Tier C — Watch / tradeNX210c
Axoltis Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AMPAR, NMDAR
Indications (approved)：Amyotrophic lateral sclerosis, Alzheimer's disease
Regional status
US
-
EU
Phase II
2024-10-25
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NX210c?
Approved indications include: Amyotrophic lateral sclerosis, Alzheimer's disease.
When does the NX210c patent expire?
No public expiry year is available for NX210c yet; this page updates once verified.
How do I get a quote for NX210c intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01